Rilonacept in cryopyrin-associated periodic syndromes: the beginning of longer-acting interleukin-1 antagonism.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Biological Therapies for Urate Lowering and Inflammation Control in Gout Management.Journal of inflammation research · 2026
   Review
2. Soluble forms of cytokine and growth factor receptors: mechanisms of generation and modes of action in the regulation of local and systemic inflammation.FEBS letters · 2022
   Review
3. Inflammasomes in the pathophysiology of autoinflammatory syndromes.Journal of leukocyte biology · 2020
   Review
4. Single-Chain Soluble Receptor Fusion Proteins as Versatile Cytokine Inhibitors.Frontiers in immunology · 2020
   Article
5. Interleukin-1 function and role in rheumatic disease.Nature reviews. Rheumatology · 2016
   Review
6. IL-1 family cytokines trigger sterile inflammatory disease.Frontiers in immunology · 2012
   Article
7. Inflammasome activation in obesity-related inflammatory diseases and autoimmunity.Discovery medicine · 2011
   Review
8. Update on biology: uric acid and the activation of immune and inflammatory cells.Current rheumatology reports · 2010
   Review

Corrections and comments

• Comment on
  Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.2008
• Comment on
  A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome.2008

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.